424B5 filed Jun 8, 2026 at 16:16 ET
Tango Therapeutics is filing a preliminary prospectus supplement for a $500M common stock offering, with an additional $75M underwriter option. The filing comes on the same day the company reported strikingly positive early Phase 1/2 clinical data for vopimetostat + daraxonrasib in MTAP-deleted/RAS-mutant pancreatic cancer (92% ORR, 90% 6-mo PFS in PDAC), which it plans to advance to Phase 3. The large equity raise creates immediate and substantial dilution (~$2.72 tangible book value per share vs. $20.22 stock price), and the preliminary nature of the filing (many terms still blank) signals the offering price is not yet set, the stock may trade down on the surprise dilutive capital need despite the positive clinical readout.